CytoDyn (CYDY) Total Current Liabilities (2011 - 2026)

CytoDyn's Total Current Liabilities history runs 16 years deep, the most recent figure standing at $50.4 million for Q1 2026.

• Quarterly Total Current Liabilities fell 28.54% year-over-year to $50.4 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $50.4 million (down 28.54% YoY) and the FY2025 annual result came in at $70.5 million, down 16.23% from the prior year.
• Total Current Liabilities was $50.4 million for Q1 2026 at CytoDyn, down from $85.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $129.5 million in Q1 2024 and bottomed at $50.4 million in Q1 2026.
• A 5-year average of $98.7 million and a median of $116.1 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities sank 46.1% — and 2025, when it climbed 20.51%.
• CytoDyn's Total Current Liabilities stood at $122.7 million in 2022, then advanced by 0.59% to $123.4 million in 2023, then tumbled by 42.77% to $70.6 million in 2024, then increased by 20.51% to $85.1 million in 2025, then plunged by 40.75% to $50.4 million in 2026.
• Business Quant data shows CYDY's Total Current Liabilities at $50.4 million in Q1 2026, $85.1 million in Q4 2025, and $69.4 million in Q3 2025.